Jonathan Gootenberg focuses on new approaches that leverage programmability across biological scales, including new nucleic acid medicines, molecular tools, and machine learning methods. These tools are applied to both fundamental questions in cell fate determination and the development of new therapeutics for genetic disease, cancer, and aging.
Jonathan Gootenberg, Ph.D., is the co-PI of the Abudayyeh-Gootenberg, an Assistant Professor at Harvard Medical School, and an Investigator at Beth Israel Deaconess Medical Center and the Center for Vaccine and Virology Research, with affiliations with the Department of Stem Cell and Regenerative Biology at Harvard University and the Department of Genetics at Brigham and Women’s Hospital. His lab explores new approaches that leverage programmability across biological scales–including new nucleic acid medicines, molecular tools, and machine learning methods–and applies them to the development of new therapeutics for genetic disease, cancer, and aging.
As a leading member of the genome editing field, he published over 50 peer-reviewed articles with over 35,000 citations, and his work has resulted in over 30 patents or patent applications. His work has been translated into 5 companies that Dr. Gootenberg has co-founded, including Sherlock Biosciences, Proof Diagnostics (acquired), and Tome Biosciences. Before his position at Harvard Medical School, Dr. Gootenberg led an independent research group at MIT as a McGovern Fellow. He received his Ph.D. in Systems Biology from Harvard University, conducting research with Aviv Regev and Feng Zhang at the McGovern Institute and Broad Institute of MIT and Harvard, and earned his bachelor’s degree in mathematics and biological engineering at MIT. Dr. Gootenberg’s work has been recognized with awards such as Forbes 30 Under 30, Technology Review 35 Under 35, Endpoints 20 Under 40, the Termeer Foundation Scholarship, and the American Association for Aging New Investigator award.